Evaluation of the rationality of drugs use inpatient patients with type 2 diabetes mellitus of 2023 at Hospital Y Depok

  • Sondang Khairani Departement of Clinical Pharmacy, Faculty of Pharmacy, Universitas Pancasila, Jakarta, 12640, Indonesia
  • Reise Manninda Departement of Clinical Pharmacy, Faculty of Pharmacy, Universitas Pancasila, Jakarta, 12640, Indonesia
  • Bitya Aulia Wijayanti Departement of Clinical Pharmacy, Faculty of Pharmacy, Universitas Pancasila, Jakarta, 12640, Indonesia
DOI: https://doi.org/10.35814/jifi.v23i1.1694

Abstract

Diabetes mellitus is a chronic disease caused by failure to control blood glucose levels. Type 2 Diabetes Mellitus (T2DM) is a condition of hyperglycemia caused by the failure of insulin to maintain balanced blood sugar levels. If T2DM is not treated it will cause complications. One way to control T2DM is the rational use of antidiabetic drugs. This study aims to look at the demographic data of inpatients with T2DM, patterns of drug use, rationality for drug use, and the relationship between the rationality of drug use and therapeutic outcomes in inpatients with T2DM at Hospital Y Depok for the period 2023. The outcome evaluated is a random blood sugar test. The research method was carried out descriptively and inferentially with a cross-sectional design. There were 122 samples that met the inclusion criteria, women predominantly suffered from type 2 diabetes mellitus (50.89%). The most common age range was 46-65 years (64.56%). As many as 84.31% of patients used the JKN payment method. The most widely used class of type 2 diabetes mellitus medication is insulin. In evaluating the rationality of using type 2 diabetes mellitus drugs, the rationality results were 99.49% correct drug, 100% correct dose, and 98.73% correct administration. The results of statistical tests show that there is a correlation between the rationality of drug use and clinical outcomes p-value 0.001.

References

[1] IDF Diabetes Atlas, 10th ed., vol. 10. International Diabetes Federation, 2021.

[2] West Java Health Office, “Number of people with diabetes mellitus by district/city in West Java .” Accessed: Aug. 07, 2023. [Online]. Available: https://opendata.jabarprov.go.id/id/dataset/jumlah-penderita-diabetes-melitus-berdasarkan-kabupatenkota-di-jawa-barat

[3] Depok City Health Office, , “Depok City Health Profile 2020,” Depok, 2020.

[4] D. B. Mamo and B. K. Alemu, “Rational drug-use evaluation based on world health organization core drug-use indicators in a Tertiary Referral Hospital, Northeast Ethiopia: A cross-sectional study,” Drug Healthc Patient Saf, vol. 12, pp. 15–21, 2020, doi: 10.2147/DHPS.S237021.

[5] S. R. Maxwell, “Rational prescribing: the principles of drug selection.,” Clin Med (Lond), vol. 16, no. 5, pp. 459–464, Oct. 2016, doi: 10.7861/clinmedicine.16-5-459.

[6] Ministry of Health Indonesia , “Rational Drug Use Module .” Ministry of Health Indonesia , Jakarta.

[7] U. Religioni and T. Pakulska, “Rational drug use in hospital settings – areas that can be changed,” J Med Econ, vol. 23, no. 10, pp. 1205–1208, Oct. 2020, doi: 10.1080/13696998.2020.1801455.

[8] D. A. Ramdini, L. K. Wahidah, and D. Atika, “Evaluation of the rationality of the use of type II diabetes mellitus drugs in outpatients at Pasir Sakti Health Centre in 2019,” Jurnal Farmasi Lampung, vol. 9, no. 1, pp. 69–76, 2020.

[9] U. Fatimah, “Evaluation of the rationality of treatment in patients with type 2 diabetes mellitus at Puskesmas Tawangsari Sukoharjo in 2021 ,” Universitas Muhammadiyah Surakarta, Surakarta, 2022.

[10] A. N. Hidayat, T. Ajeng L, and K. Siwi, “ Evaluation of the rationality of oral antidiabetic drugs on the effectiveness of therapy for patients with type II diabetes mellitus at RSUD Dr Moewardi Surakarta ,” Jambura Journal of Health Science and Research, vol. 5, no. 3, pp. 815–824, 2023, [Online]. Available: https://ejurnal.ung.ac.id/index.php/jjhsr/index

[11] S. Khairani, R. Manninda, L.J. Raharjo, A.F. Widodo, “ Cost effectiveness analysis of ceftriaxone with cefoperazon in thypoid patients at X Mataram Hospital”, Jurnal Ilmu Kefarmasian Indonesia, vol 22, no 1, pp. 163-168. 2024

[12 ] A. Kautzky-Willer, M. Leutner, and J. Harreiter, “Sex differences in type 2 diabetes,” Diabetologia, vol. 66, no. 6, pp. 986–1002, Jun. 2023, doi: 10.1007/s00125-023-05891-x.

[13] D. C. Lee et al., “Age Disparities Among Patients With Type 2 Diabetes and Associated Rates of Hospital Use and Diabetic Complications,” Prev Chronic Dis, vol. 16, p. 180681, Aug. 2019, doi: 10.5888/pcd16.180681.

[14] F. Megawati, P. T. Suwantara, and N. L. S. A. Suryani, “Comparıson Of Cost Rates For Patıents Wıth Dıabetes Mellıtus In General Hospıtalısatıon And Bpjs In One Of The Publıc Hospıtals In Denpasar Perıod 2019,” Jurnal Ilmiah Medicamento, vol. 6, no. 2, pp. 100–105, 2020.

[15] L. Nagendra, H. Boro, and V. Mannar, Bacterial Infections in Diabetes. 2000.

[16] G. Liamis, “Diabetes mellitus and electrolyte disorders,” World J Clin Cases, vol. 2, no. 10, p. 488, 2014, doi: 10.12998/wjcc.v2.i10.488.

[17] R. T. Varghese and I. Jialal, Diabetic Nephropathy. 2024.

[18] K. S. Wan et al., “Prevalence of diabetic kidney disease and the associated factors among patients with type 2 diabetes in a multi-ethnic Asian country,” Sci Rep, vol. 14, no. 1, p. 7074, Mar. 2024, doi: 10.1038/s41598-024-57723-6.

[19] Indonesian Endocrine Society, “Practical Guidelines for Insulin Therapy in Diabetes Mellitus Patients 2021” .Perkeni, 2021.

[20] Indonesian Endocrine Society , Guidelines for the Management and Prevention of Adult Type 2 Diabetes Mellitus in Indonesia - 2021 . PB. Perkeni, 2021.

[21] A. Anisawati, K. J. Pratama, and K. S. Artini, “Evaluation of Antidiabetic Rationality for Outpatients with Type 2 Diabetes Mellitus at RSAU dr. Siswanto in 2022 ,” in Prosiding Nasional SIKesNas , 2023, pp. 84–92. doi: doi.org/10.47701/sikenas.vi.2835.

[22] C. Pratiwi, M. I. Mokoagow, I. A. Made Kshanti, and P. Soewondo, “The risk factors of inpatient hypoglycemia: A systematic review,” Heliyon, vol. 6, no. 5, p. e03913, May 2020, doi: 10.1016/j.heliyon.2020.e03913.
Published
2025-04-30
How to Cite
KHAIRANI, Sondang; MANNINDA, Reise; WIJAYANTI, Bitya Aulia. Evaluation of the rationality of drugs use inpatient patients with type 2 diabetes mellitus of 2023 at Hospital Y Depok. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 23, n. 1, p. 92-98, apr. 2025. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1694>. Date accessed: 24 may 2025. doi: https://doi.org/10.35814/jifi.v23i1.1694.
Citation Formats
Issue
Vol 23 No 1 (2025): JIFI In press
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.